A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). [electronic resource]
Producer: 20170106Description: 475-82 p. digitalISSN:- 1463-1326
- Aged
- Diabetes Mellitus, Type 2 -- blood
- Double-Blind Method
- Drug Administration Schedule
- Drug Resistance
- Drug Therapy, Combination -- adverse effects
- Female
- Glucagon-Like Peptide-1 Receptor -- metabolism
- Glucagon-Like Peptides -- administration & dosage
- Glycated Hemoglobin -- analysis
- Humans
- Hyperglycemia -- prevention & control
- Hypoglycemia -- chemically induced
- Hypoglycemic Agents -- administration & dosage
- Immunoglobulin Fc Fragments -- administration & dosage
- Injections, Subcutaneous
- Intention to Treat Analysis
- Male
- Middle Aged
- Patient Dropouts
- Recombinant Fusion Proteins -- administration & dosage
- Sulfonylurea Compounds -- adverse effects
- Glucagon-Like Peptide-1 Receptor Agonists
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.